Jodie Pang - Concepedia

Author

Jodie Pang

Also Known As

J Pang, J. Pang, Jiaping Pang, Jiaqian Pang, Jie Pang, Jingjie Pang, Jinguo Pang, Jingyan Pang, Jodie Pang, L. Sanchez-Perez

111

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Xenon Pharmaceuticals (Canada)Charles River Laboratories (United Kingdom)WuXi AppTec (China)Gene Therapy Laboratory Shanghai Zhangjiang Laboratory

About

Jodie Pang is an author at Xenon Pharmaceuticals (Canada) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	25	2.5K
2	Cell Biology	9	9	901
3	Biochemistry	7	7	592
4	Natural Sciences	5	5	169
5	Health Sciences	1	1	71

Jodie Pang

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer Adrian Folkes, Khatereh Ahmadi, W. Alderton, Journal of Medicinal Chemistry Pi3 KinaseChemoprevention StrategyPharmacotherapyPharmaceutical ChemistryTumor Biology	2008	739
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition Aaron Boudreau, Hans E. Purkey, A. Hitz, Nature Chemical Biology Systems BiologyBiochemistryLdha InhibitionLipid PeroxidationMetabolic Regulation	2016	251
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan, Molecular Cancer Therapeutics Chemoprevention StrategyCancer BiologyPd BiomarkersTumor BiologyOncology	2011	226
Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer Daniel P. Sutherlin, Linda Bao, Megan Berry, Journal of Medicinal Chemistry Translational PharmacologyPre-clinical PharmacologyMolecular PharmacologyMedicinal ChemistryReceptor Tyrosine Kinase	2011	212
Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity Chudi Ndubaku, Timothy P. Heffron, Steven T. Staben, Journal of Medicinal Chemistry Drug TargetUnbound Drug ExposurePharmacotherapyIntrinsic ClearanceTumor Biology	2013	174
Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer Daniel P. Sutherlin, Deepak Sampath, Megan Berry, Journal of Medicinal Chemistry	2010	131
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα Emily J. Hanan, Marie-Gabrielle Braun, Robert A. Heald, Journal of Medicinal Chemistry	2022	119
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR Timothy P. Heffron, Chudi Ndubaku, Laurent Salphati, ACS Medicinal Chemistry Letters Pi3k InhibitorsChemoprevention StrategyPoor Metabolic StabilityNeurochemical BiomarkersHigh-grade Gliomas	2016	104
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of ( <i>S</i> )-2-((2-(1-Isopropyl-1 <i>H</i> -1,2,4-triazol-5-yl)-5,6-dihydrobenzo[ <i>f</i> ]imidazo[1,2- <i>d</i> ][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326) Timothy P. Heffron, Robert A. Heald, Chudi Ndubaku, Journal of Medicinal Chemistry	2016	102
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor Timothy P. Heffron, Megan Berry, Georgette M. Castanedo, Bioorganic & Medicinal Chemistry Letters BiochemistryG Protein-coupled ReceptorMedicineFunctional SelectivityMechanism Of Action	2010	88

Page 1